Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Kura Oncology, Inc. (NASDAQ:KURA) has earned a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have given a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $25.5833.

A number of analysts have commented on KURA shares. UBS Group reaffirmed a “buy” rating and set a $15.00 price objective (down from $16.00) on shares of Kura Oncology in a research note on Friday, March 13th. Lake Street Capital started coverage on shares of Kura Oncology in a research report on Tuesday, April 14th. They issued a “buy” rating and a $23.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Kura Oncology in a research report on Tuesday, April 21st. Oppenheimer set a $24.00 price target on shares of Kura Oncology in a research report on Thursday, May 28th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Kura Oncology in a research report on Thursday, June 4th.

Kura Oncology Price Performance

KURA stock opened at $9.05 on Monday. The company has a current ratio of 6.15, a quick ratio of 6.14 and a debt-to-equity ratio of 0.09. Kura Oncology has a one year low of $5.45 and a one year high of $12.49. The firm has a market capitalization of $803.37 million, a PE ratio of -2.70 and a beta of 0.36. The firm has a 50-day moving average of $9.31 and a two-hundred day moving average of $9.33.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. The company had revenue of $18.27 million during the quarter, compared to analyst estimates of $25.97 million. On average, analysts forecast that Kura Oncology will post -3.47 earnings per share for the current year.

Institutional Trading of Kura Oncology

Hedge funds have recently made changes to their positions in the stock. IFP Advisors Inc lifted its position in shares of Kura Oncology by 115.3% in the fourth quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock worth $25,000 after purchasing an additional 1,284 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Kura Oncology by 392.8% in the third quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after purchasing an additional 3,072 shares in the last quarter. Allworth Financial LP lifted its position in shares of Kura Oncology by 59.9% in the fourth quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock worth $43,000 after purchasing an additional 1,553 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Kura Oncology by 127.2% in the third quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock worth $60,000 after purchasing an additional 3,769 shares in the last quarter. Finally, Tower Research Capital LLC TRC lifted its position in shares of Kura Oncology by 471.3% in the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after purchasing an additional 9,958 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.